1. Home
  2. STEX vs FBIO Comparison

STEX vs FBIO Comparison

Compare STEX & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STEX

Streamex Corp.

N/A

Current Price

$3.46

Market Cap

127.3M

Sector

N/A

ML Signal

N/A

Logo Fortress Biotech Inc.

FBIO

Fortress Biotech Inc.

HOLD

Current Price

$3.48

Market Cap

113.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEX
FBIO
Founded
2009
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
127.3M
113.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
STEX
FBIO
Price
$3.46
$3.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$12.00
$16.50
AVG Volume (30 Days)
713.5K
1.2M
Earning Date
02-17-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,000.00
$62,303,000.00
Revenue This Year
N/A
$29.71
Revenue Next Year
N/A
$49.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$1.33
52 Week High
$14.11
$4.53

Technical Indicators

Market Signals
Indicator
STEX
FBIO
Relative Strength Index (RSI) N/A 47.17
Support Level N/A $3.33
Resistance Level N/A $3.79
Average True Range (ATR) 0.00 0.33
MACD 0.00 -0.11
Stochastic Oscillator 0.00 18.36

Price Performance

Historical Comparison
STEX
FBIO

About STEX Streamex Corp.

Streamex Corp is a vertically integrated technology and infrastructure company. It is focused on the tokenization and digitalization of real-world assets. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.

About FBIO Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

Share on Social Networks: